US Patent Issued to BIOMEA FUSION on March 18 for "Covalent inhibitors of menin-MLL interaction for diabetes mellitus" (American, Australian Inventors)

ALEXANDRIA, Va., March 19 -- United States Patent no. 12,251,385, issued on March 18, was assigned to BIOMEA FUSION INC. (Redwood City, Calif.).

"Covalent inhibitors of menin-MLL interaction for diabetes mellitus" was invented by Thomas Butler (Redwood City, Calif.) and James T. Palmer (Warrandyte, Australia).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors a...